Literature DB >> 699478

Dose-dependent acebutolol disposition after oral administration.

P J Meffin, R A Winkle, F A Peters, D C Harrison.   

Abstract

The relationship between dose and area under the blood concentration-time curve has been studied in 6 healthy subjects following both oral and intravenous doses of acebutolol. There is a more than proportional increase in area with increasing oral doses, and the area over a dosing interval following multiple oral doses is greater than the total area after a single dose of the same size. The role of an acetyl metabolite in producing these effects is discussed, as is the relevance of these observations to the clinical use of acebutolol.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 699478     DOI: 10.1002/cpt1978245542

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

1.  Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers.

Authors:  J Godbillon; A Gerardin; V A John; W Theobald
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

2.  A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol.

Authors:  M J Kendall; V A John; C P Quarterman; P G Welling
Journal:  Eur J Clin Pharmacol       Date:  1980-02       Impact factor: 2.953

3.  Pharmacokinetics and bioavailability of diacetolol, the main metabolite of acebutolol.

Authors:  B Flouvat; A Roux; N P Chau; M Viallet; X Andre-Fouet; R Woehrle; J Gregoire
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

4.  Pharmacokinetics of acebutolol in patients with all grades of renal failure.

Authors:  A Roux; P Aubert; J Guedon; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1980-05       Impact factor: 2.953

Review 5.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

6.  Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination.

Authors:  A Roux; A Le Liboux; B Delhotal; J Gaillot; B Flouvat
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  A multiple dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers.

Authors:  K L Woods; D B Jack; M J Kendall; A Halsey; M L O'Donnell; S J Warrington; V A John
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Observations on the clinical pharmacology and plasma concentrations of diacetolol, the major human metabolite of acebutolol.

Authors:  K Ohashi; S J Warrington; C M Kaye; G W Houghton; M Dennis; R Templeton; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

9.  Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.

Authors:  J Mattila; R Mäntylä; J Taskinen; P Männistö
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Apr-Jun       Impact factor: 2.441

10.  Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.

Authors:  M J Kendall; D B Jack; K L Woods; S J Laugher; C P Quarterman; V A John
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.